Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EPS (Basic) (2020 - 2025)

Maravai Lifesciences Holdings has reported EPS (Basic) over the past 6 years, most recently at -$0.24 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.24 for Q4 2025, down 33.33% from a year ago — trailing twelve months through Dec 2025 was -$0.9 (up 11.76% YoY), and the annual figure for FY2025 was -$0.9, up 14.29%.
  • EPS (Basic) for Q4 2025 was -$0.24 at Maravai Lifesciences Holdings, down from -$0.18 in the prior quarter.
  • Over the last five years, EPS (Basic) for MRVI hit a ceiling of $0.54 in Q2 2022 and a floor of -$0.8 in Q4 2023.
  • Median EPS (Basic) over the past 5 years was -$0.05 (2023), compared with a mean of $0.02.
  • Biggest five-year swings in EPS (Basic): soared 7647.81% in 2021 and later tumbled 1260.0% in 2024.
  • Maravai Lifesciences Holdings' EPS (Basic) stood at $0.43 in 2021, then crashed by 34.88% to $0.28 in 2022, then crashed by 385.71% to -$0.8 in 2023, then soared by 77.5% to -$0.18 in 2024, then plummeted by 33.33% to -$0.24 in 2025.
  • The last three reported values for EPS (Basic) were -$0.24 (Q4 2025), -$0.18 (Q3 2025), and -$0.27 (Q2 2025) per Business Quant data.